In light of the coronavirus disease 2019 (COVID-19) pandemic, pharmacies have implemented new strategies to ensure their patients continue to receive care, especially for those who have lost their insurance or have underlying conditions.
As many Americans are out of work and losing their health insurance due to the coronavirus disease 2019 (COVID-19) pandemic, pharmacies are finding ways to adapt and step up to the challenge in order to ensure that patients receive their treatments, panelists said Wednesday during the Pharmacy Quality Alliance (PQA) 2020 Annual Meeting.
Currently, there are over 20 million Americans out of work due to the pandemic, many of whom were covered by employer-provided health care plans and will now be eligible for Medicaid under the Affordable Care Act.
Many patients are suddenly unsure of how to continue their care, and Bruce Japsen, a senior health care writer for Forbes, suggested checking the government health care websites to find out what benefits they are eligible for.
“We don’t want a co-pay to get in the way. We don’t want a deductible to get in the way. And we certainly don’t want them to…not go to the doctor [or get] care because they don’t think [primary care providers are] open or they’re afraid to leave their house,” said Japsen.
Changes to the Pharmacy Structure
Japsen mentioned that pharmacies are expected to do well during the pandemic because they are classified as essential businesses and may remain open.
Some pharmacies “saw a huge uptick in people getting their prescriptions because some insurance companies allowed people to get prescriptions for several months rather than 1 or 2. So then, guess what happened in April? They had fewer people coming to the store, which was kind of hurting their business,” he said.
Pharmacies have had to change how they run their business entirely, from exclusively using drive-throughs to investing in telemedicine and medication deliveries.
Pharmacies have also become testing centers for COVID-19 and may be points of access for vaccines. Benjamin McNabb, PharmD, the owner of Love Oak Pharmacy in Eastland, Texas, wants pharmacies to keep those designations and hopes pharmacies will provide greater access to vaccines and tests.
“I would like to see pharmacies be given that opportunity to maintain that designation and possibly enter into other point-of-care testing like for [glycated hemoglobin] and cholesterol testing. There’s a lot of things that pharmacists can do,” he said.
McNabb expects that that some storefronts for pharmacies, including his own, will reopen in the next few weeks, meaning that procedural changes will be needed.
“We have to think about requiring patients to wear masks as they enter. We will most likely have to have an employee stationed at the front door instructing people. Can we help clean their hands with a spray bottle of alcohol, since some of the sanitizers are hard to find?” he said.
Pharmacies across the nation will also have to contend with establishing capacity levels for reopening, as restaurants and stores are doing.
How Pharmacies Have Risen to the Challenge
McNabb pointed out that certain pharmacies have received government approval to produce their own hand sanitizers for the public in light of shortages during the pandemic.
“Nearly half of all independent pharmacies are still compounding pharmacies, and they’re making quite a bit of hand sanitizer. Many of them are donating it to their communities, their patients, local businesses, and health care first responders,” he said.
Additionally, pharmacies, especially in rural areas, have made continued efforts to maintain local relationships, which is more critical than people realize, according to McNabb.
“In certain rural areas where phone and internet access might be limited, it’s sometimes patients, especially the highest-need patients, who are the costliest….Achieving the best outcome possible is very difficult to do, sometimes, through telephonic means,” said McNabb.
Some, including McNabb’s pharmacy, have expanded their delivery services and telemedicine to include pharmacy personnel in order to ensure continued treatment management for at-home patients. Drivers can give information on health care and can provide blood pressure screenings for individuals at home.
“I think there’s a void that we can fill to partner with telemedicine, to partner with local physicians, especially in chronic disease management,” said McNabb.
Pharmacies have also taken initiative to ensure treatment for patients with underlying conditions who are considered to be at higher risk of developing COVID-19—related complications by encouraging use of value-based patient models.
“I think an interesting thing to be thinking about is how are we managing underlying health conditions that might be exacerbated by COVID-19? So, partnering with pharmacists for these guide-based delivery models, I think, is invaluable,” said McNabb.
EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions
June 27th 2024Two posters presented at the European Hematology Association’s annual meeting (EHA 2024) evaluated how rituximab biosimilars impact quality of life and infusion-related reactions in patients with lymphatic cancers.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
EHA Poster Shows Transfusion Avoidance Rates Were Comparable Between Eculizumab Biosimilar, Soliris
Published: June 15th 2024 | Updated: June 14th 2024A poster from the European Hematology Association’s (EHA) 2024 annual meeting in Madrid, Spain, showed similar rates of transfusion avoidance between patients with paroxysmal nocturnal hemoglobinuria who were administered reference eculizumab (Soliris) and those administered an eculizumab biosimilar (SB12).
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Posters Capture Clinical Impacts of Infliximab in Super-Responders, Pregnant Patients With IBD
June 1st 2024Posters from Digestive Disease Week 2024 look at how super-responders and pregnant patients with inflammatory bowel disease (IBD) react to treatment with subcutaneous infliximab and an infliximab biosimilar, respectively.